Evidence map›Paper›PMID 40631526›Full record

ArticlePharmacology research & perspectives2025

Extending Investigations of miR-126-5p on the Regulation of CYP2A6, the Major Nicotine-Inactivating Enzyme.

Weilong Gu, Alec W R Langlois, Haidy Giratallah, Katrina G Claw, Bhagwat Prasad, Kenneth E Thummel, Rachel F Tyndale

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weilong GuDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0009-0001-2134-9629
Alec W R LangloisDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Haidy GiratallahDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Katrina G ClawDepartment of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Bhagwat PrasadDepartment of Pharmaceutics, University of Washington, Washington, USA.
Kenneth E ThummelDepartment of Pharmaceutics, University of Washington, Washington, USA.
Rachel F TyndaleDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-1297-2053

Funding

Canada Research ChairsCIHR FDN-154294CIHR PJY-159710FIC NIH HHS PGRN DA020830
6 · The paper itself

Abstract

CYP2A6 is the hepatic enzyme responsible for the metabolic inactivation of nicotine. Variation in CYP2A6 alters nicotine clearance, affecting numerous smoking behaviors and tobacco-related diseases, making investigating sources of variation important. A published molecular study of microRNA-126-5p, the microRNA-126 functional arm, showed it decreased CYP2A6 expression post-transcriptionally; it also showed that higher CYP2A7 mRNA competed for microRNA-126-5p binding, mitigating the CYP2A6 reduction. To extend these observations, we investigated relationships between microRNA-126-5p and CYP2A6 protein and activity using a large human liver bank (n = 282). MicroRNA-126-5p was not inversely correlated with CYP2A6 protein (r

Indexed as

Cytochrome P-450 CYP2A6MicroRNAsNicotineAdultAgedFemaleHumansLiverMaleMiddle AgedRNA, MessengerCYP2A6 protein, humanCytochrome P-450 CYP2A6MicroRNAsMIRN126 microRNA, humanNicotineRNA, Messenger

Identifiers

PMID40631526
PMCPMC12238898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.